Predicting the outcome of Sjogren's syndrome-associated non-Hodgkin's lymphoma patients

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Papageorgiou, Aristea ^a   Ziogas, Dimitrios C ^a   Mavragani, Clio P ^a   Zintzaras, Elias ^b   Tzioufas, Athanasios G ^a   Moutsopoulos, Haralampos M ^a   Voulgarelis, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SJOEGREN SYNDROME; VERY ELDERLY; WORLD HEALTH ORGANIZATION; COMPLICATION; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; SJOGREN'S SYNDROME; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; RETROSPECTIVE STUDIES; SJOGREN'S SYNDROME; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84923815362     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116189     Document Type: Article

References (45)

1. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM (2000) Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 29: 296-304. PMID: 10805354
2. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM (1996) Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 39: 767-772. PMID: 8639173
3. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999) Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 42: 1765-1772. PMID: 10446879
4. Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 46: 741-747. PMID: 11920410
5. Theander E, Manthorpe R, Jacobsson LT (2004) Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 50: 1262-1269. PMID: 15077310
6. Ramos-Casals M, Brito-Zeron P, Yague J, Akasbi M, Bautista R, et al. (2005) Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 44: 89-94. PMID: 15381790
7. Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J (2007) Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 46: 1359-1362. PMID: 17569749
8. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, et al. (2006) Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65: 796-803. PMID: 16284097
9. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, et al. (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98: 51-60. PMID: 16391371
10. Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, et al. (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111: 4029-4038. doi: 10.1182/blood-2007-10-119974 PMID: 18263783
11. Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, et al. (2009) Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 125: 398-405. doi: 10.1002/ijc.24287 PMID: 19365835
12. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, et al. (1997) Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 90: 766-775. PMID: 9226177
13. Solans-Laque R, Lopez-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, et al. (2011) Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 41: 415-423. doi: 10.1016/j.semarthrit.2011.04.006 PMID: 21665245
14. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88: 284-293. doi: 10.1097/MD.0b013e3181b76ab5 PMID: 19745687
15. Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165: 2337-2344. PMID: 16287762
16. Zufferey P, Meyer OC, Grossin M, Kahn MF (1995) Primary Sjogren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol 24: 342-345. PMID: 8610217
17. Hernandez JA, Olive A, Ribera JM, Tena X, Cuxart A, et al. (1996) Probability of the development of non-Hodgkin's lymphoma in primary Sjogren's syndrome. Scand J Rheumatol 25: 396-397. PMID: 8996477
18. Kruize AA, Hene RJ, van der Heide A, Bodeutsch C, de Wilde PC, et al. (1996) Long-term followup of patients with Sjogren's syndrome. Arthritis Rheum 39: 297-303. PMID: 8849383
19. Sutcliffe N, Inanc M, Speight P, Isenberg D (1998) Predictors of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 28: 80-87. PMID: 9806368
20. Martens PB, Pillemer SR, Jacobsson LT, O'Fallon WM, Matteson EL (1999) Survivorship in a population based cohort of patients with Sjogren's syndrome, 1976-1992. J Rheumatol 26: 1296-1300. PMID: 10381046
21. Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, et al. (2012) Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore) 91: 1-9.
22. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, et al. (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-558. PMID: 12006334
23. Jaffe ES (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program: 523-531.
24. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655. PMID: 7165009
25. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31: 1860-1861. PMID: 5121694
26. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329: 987-994. PMID: 8141877
27. Daniels TE, Whitcher JP (1994) Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjogren's syndrome. Arthritis Rheum 37: 869-877. PMID: 8003059
28. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, et al. (2010) EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 69: 1103-1109. doi: 10.1136/ard.2009.110619 PMID: 19561361
29. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244. PMID: 10561185
30. Pollard RP, Pijpe J, Bootsma H, Spijkervet FK, Kluin PM, et al. (2011) Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study. J Rheumatol 38: 2198-2208. doi: 10.3899/jrheum.110077 PMID: 21844152
31. Ambrosetti A, Zanotti R, Pattaro C, Lenzi L, Chilosi M, et al. (2004) Most cases of primary salivary mu-cosa- associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol 126: 43-49. PMID: 15198730
32. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, et al. (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89: 888-892. PMID: 102228
33. Gottenberg JE, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, et al. (2013) Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 8: e59868. doi: 10.1371/journal.pone.0059868 PMID: 23717383
34. Tobon GJ, Saraux A, Gottenberg JE, Quartuccio L, Fabris M, et al. (2013) Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 65: 3218-3227. doi: 10.1002/art.38129 PMID: 23982978
35. Ramos-Casals M, Brito-Zeron P, Solans R, Camps MT, Casanovas A, et al. (2014) Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 53: 321-331. doi: 10.1093/ rheumatology/ket349 PMID: 24162151
36. Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, et al. (2013) Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 72: 728-735. doi: 10.1136/annrheumdis-2012-201381 PMID: 22736090
37. Troch M, Wohrer S, Raderer M (2010) Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma. Anticancer Res 30: 635-639. PMID: 20332482
38. Thieblemont C (2005) Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program: 307-313.
39. Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, et al. (2000) Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95: 802-806. PMID: 10648389
40. Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, et al. (2003) Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101: 2489-2495. PMID: 12456507
41. de Boer JP, Hiddink RF, Raderer M, Antonini N, Aleman BM, et al. (2008) Dissemination patterns in non-gastric MALT lymphoma. Haematologica 93: 201-206. doi: 10.3324/haematol.11835 PMID: 18223283
42. Gill H, Chim CS, Au WY, Loong F, Tse E, et al. (2011) Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results. Ann Hematol 90: 1399-1407. doi: 10.1007/s00277-011-1226-z PMID: 21476016
43. Wohrer S, Troch M, Streubel B, Zwerina J, Skrabs C, et al. (2007) MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. Leukemia 21: 1812-1818. PMID: 17554381
44. Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, et al. (1999) Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 17: 1254. PMID: 10561186
45. Risselada AP, Kruize AA, Bijlsma JW (2013) Clinical features distinguishing lymphoma development in primary Sjogren's Syndrome-a retrospective cohort study. Semin Arthritis Rheum 43: 171-177. doi: 10.1016/j.semarthrit.2013.03.001 PMID: 23664530